Status:
COMPLETED
A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood level...
Eligibility Criteria
Inclusion
- Adult with RA for at least 6 months
- Stable weekly dosage of oral methotrexate 12.5- 25 mg/week
Exclusion
- Severe, progressive and/or uncontrolled other disease
- Chronic or recent serious infection; current infection
- Concomitant use of RA therapy other than methotrexate with some exceptions
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00620685
Start Date
March 1 2008
End Date
October 1 2008
Last Update
November 8 2018
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Phoenix, Arizona, United States, 85013
2
Pfizer Investigational Site
Colorado Springs, Colorado, United States, 80909
3
Pfizer Investigational Site
Miami, Florida, United States, 33169
4
Pfizer Investigational Site
Frederick, Maryland, United States, 21702